Business
PAVmed Provides Business Update and First Quarter Financial Results
EsoGuard® test volume gains momentum as Lucid expands high-volume testing events PAVmed appoints President for Veris Health and expands commercial footprint
About this update from Pavmed Inc.
[{"type":"text","content":"EsoGuard® test volume gains momentum as Lucid expands high-volume testing events\nPAVmed appoints President for Veris Health and expands commercial footprint\nConference call and webcast to be held tomorrow, May 17th at 8:30 AM EST\nNEW YORK, May 16, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) (\"PAVmed\" or the \"Company\"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) (\"Lucid\") and Veris Health Inc. (\"Veris\"), and presented financial results for the Company for the three months ended March 31, 2023.\n\n \n \n \n \n \n \n\n \nConference Call and Webcast\nThe webcast will take place on Wednesday, May 17, 2023, at 8:30 AM and will be accessible in the investor relations section of the Company's website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-866-652-5200 and international listeners should dial 412-317-6060. All listeners should provide the operator with the conference call name \"PAVmed Business Update\" to join.\nBusiness Update Highlights\n\"Since our business update in January, the PAVmed team has continued to execute on our near-term strategy focused on our two commercial subsidiaries, Lucid and Veris, to fulfill our vision to build a high-growth, diversified medical technology company,\" said Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer. \"To that end, we continue to expand utilization of our Veris Cancer Care Platform, while broadening our long-term commercial strategy under the leadership of our new Veris President, Gary Manning. Similarly, Lucid continues to accelerate test volume growth, including through an expanded use of satellite Lucid Test Centers (sLTC) and #CheckYourFoodTube events. Collectively, the teams are delivering on key metrics while continuing to preserve cash even as we press through near-term inflection points.\"\nHighlights from the first quarter and recent weeks include:\nSince the Veris Cancer Care Platform went \"live\" in February, Veris added two additional accounts, expanding utilization of the product to a total of six locations across three oncology practices while building a robust, nationwide pipel...